These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29469225)

  • 21. Myeloablative BU, fludarabine, antithymocyte globulin and low-dose TBI in the treatment of juvenile myelomonocytic leukaemia with allogeneic haematopoietic cell transplantation.
    Guilcher GM; Moorjani R; Truong TH; Lewis VA
    Bone Marrow Transplant; 2015 Mar; 50(3):455-6. PubMed ID: 25486583
    [No Abstract]   [Full Text] [Related]  

  • 22. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.
    Ciurea SO; Saliba R; Rondon G; Pesoa S; Cano P; Fernandez-Vina M; Qureshi S; Worth LL; McMannis J; Kebriaei P; Jones RB; Korbling M; Qazilbash M; Shpall EJ; Giralt S; de Lima M; Champlin RE; Gajewski J
    Bone Marrow Transplant; 2010 Mar; 45(3):429-36. PubMed ID: 19668237
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term outcomes of fludarabine, melphalan and antithymocyte globulin as reduced-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with primary immunodeficiency disorders: a prospective single center study.
    Hamidieh AA; Behfar M; Pourpak Z; Faghihi-Kashani S; Fazlollahi MR; Hosseini AS; Movahedi M; Mozafari M; Moin M; Ghavamzadeh A
    Bone Marrow Transplant; 2016 Feb; 51(2):219-26. PubMed ID: 26595073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of two doses of anti-T lymphocyte globulin-Fresenius given after full-match sibling stem cell transplantation in acute myeloblastic leukemia patients who underwent myeloablative fludarabine/busulfan conditioning.
    Boga C; Yeral M; Gereklioglu C; Asma S; Maytalman E; Aytan P; Kozanoglu I; Sariturk C; Ozdogu H
    Hematol Oncol Stem Cell Ther; 2018 Sep; 11(3):149-157. PubMed ID: 29474820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis.
    Schetelig J; Bornhäuser M; Kiehl M; Schwerdtfeger R; Kröger N; Runde V; Zabelina T; Held TK; Thiede C; Fauser AA; Beelen D; Zander A; Ehninger G; Siegert W;
    Bone Marrow Transplant; 2004 Mar; 33(5):483-90. PubMed ID: 14716342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treosulfan and Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Children with Primary Immunodeficiency: UK Experience.
    Slatter MA; Rao K; Abd Hamid IJ; Nademi Z; Chiesa R; Elfeky R; Pearce MS; Amrolia P; Worth A; Flood T; Abinun M; Hambleton S; Qasim W; Gaspar HB; Cant AJ; Gennery AR; Veys P
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):529-536. PubMed ID: 29155317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-total body irradiation myeloablative conditioning with intravenous busulfan and cyclophosphamide in hematopoietic stem cell transplantation for malignant infantile osteopetrosis.
    Behfar M; Dehghani SS; Hosseini AS; Jalali A; Hamidieh AA; Ghavamzadeh A
    Pediatr Transplant; 2015 Jun; 19(4):422-7. PubMed ID: 25879376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.
    Ishida H; Adachi S; Hasegawa D; Okamoto Y; Goto H; Inagaki J; Inoue M; Koh K; Yabe H; Kawa K; Kato K; Atsuta Y; Kudo K
    Pediatr Blood Cancer; 2015 May; 62(5):883-9. PubMed ID: 25545836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin.
    Soni S; Gross TG; Rangarajan H; Baker KS; Sturm M; Rhodes M
    Pediatr Blood Cancer; 2014 Sep; 61(9):1685-9. PubMed ID: 24740582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical effect of reduced-intensity conditioning regimen containing antithymocyte globulin for hematopoietic cell transplantation from unrelated-donors.
    Lee KH; Choi SJ; Lee JH; Lee JH; Kim DY; Seol M; Lee YS; Kang YA; Jeon M; Yun SC; Joo YD; Lee WS; Kang MJ; Kim H; Park JH; Bae SH; Ryoo HM; Kim MK; Hyun MS
    Am J Hematol; 2011 May; 86(5):399-405. PubMed ID: 21523798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience.
    Rzepecki P; Sarosiek T; Szczylik C
    Jpn J Clin Oncol; 2006 Jan; 36(1):46-9. PubMed ID: 16423840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party.
    Rubio MT; D'Aveni-Piney M; Labopin M; Hamladji RM; Sanz MA; Blaise D; Ozdogu H; Daguindeau E; Richard C; Santarone S; Irrera G; Yakoub-Agha I; Yeshurun M; Diez-Martin JL; Mohty M; Savani BN; Nagler A
    J Hematol Oncol; 2017 Jan; 10(1):31. PubMed ID: 28118857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Different Conditioning Regimens of Haploidentical Hematopoietic Stem Cell Transplant in Patients With Acute Myeloid Leukemia.
    Jiang Y; Fang X; Sui X; Liu X; Li Y; Wang X; Xu H; Zhang L; Wang X
    Exp Clin Transplant; 2018 Dec; 16(6):736-744. PubMed ID: 29790457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Allogeneic stem cell transplantation for 8 patients with malignant infantile osteopetrosis in China].
    Zhu GH; Qin MQ; Wang B; Zhou X; Yang J; Jia CG; Wu Y; Wang XS; Wu MY
    Zhonghua Er Ke Za Zhi; 2012 Nov; 50(11):807-12. PubMed ID: 23302608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of fludarabine- and busulfan-based conditioning regimens in patients with acute myeloblastic leukemia: 8-year experience in a single center.
    Kasar M; Asma S; Kozanoglu I; Maytalman E; Boga C; Ozdogu H; Yeral M
    Transplant Proc; 2015 May; 47(4):1217-21. PubMed ID: 26036558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of new flu-bu12-tg conditioning with the standard bu-cy myeloablative regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia.
    Raida L; Tucek P; Faber E; Vondrakova J; Rusinakova Z; Skoumalova I; Hubacek J; Jarosova M; Katrincsakova B; Pikalova Z; Kurfurst P; Indrak K
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Dec; 155(4):327-32. PubMed ID: 22336644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases.
    Crocchiolo R; Esterni B; Castagna L; Fürst S; El-Cheikh J; Devillier R; Granata A; Oudin C; Calmels B; Chabannon C; Bouabdallah R; Vey N; Blaise D
    Cancer; 2013 Mar; 119(5):986-92. PubMed ID: 23096591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allogeneic stem cell transplantation for patients with advanced hematological malignancies: comparison of fludarabine-based reduced intensity conditioning versus myeloablative conditioning.
    Kim I; Lee KH; Choi Y; Keam B; Koo NH; Yoon SS; Yoo KY; Park S; Kim BK
    J Korean Med Sci; 2007 Apr; 22(2):227-34. PubMed ID: 17449929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma.
    Ayala E; Figueroa J; Perkins J; Kim J; Yue B; Riches M; Nishihori T; Locke F; Anasetti C; Kharfan-Dabaja MA
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):335-40. PubMed ID: 25659459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.